⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Preoperative Thalidomide Followed By Radical Retropubic Prostatectomy In Select Patients With Locally Advanced Prostate Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Preoperative Thalidomide Followed By Radical Retropubic Prostatectomy In Select Patients With Locally Advanced Prostate Cancer

Official Title: A Tolerance and Efficacy Trial of Preoperative Thalidomide Treatment Followed by Radical Retropubic Prostatectomy (RRP) in Select Patients With Locally Advanced Prostate Cancer

Study ID: NCT00038181

Conditions

Prostate Cancer

Interventions

Thalidomide

Study Description

Brief Summary: The goal of this clinical research study is to find out whether it is safe to treat patients diagnosed with locally advanced prostate cancer with the drug Thalidomide before removing the tumor (radical retropubic prostatectomy). Researchers also want to learn if Thalidomide can shrink or slow the growth of the prostate cancer before the surgery

Detailed Description: 1. To determine the efficacy (rate of tumor reduction and PSA decline) of pre-operative treatment with thalidomide in patients with locally advanced prostate carcinoma. 2. To determine the safety and toxicity (excessive bleeding, wound healing problems) of preoperative therapy with thalidomide in patients with locally advanced prostate carcinoma who undergo RRP. 3. To obtain qualitative measurements of thalidomide's effect in vivo on: 1. endothelial cells / neo-vascularity /angiogenic growth factors: * Assessment of neovascularity (MVD) * Dual fluorescent labeling technique to evaluate apoptosis in CD-31 positive cells (TUNEL) * bFGF, VEGF, EGF and TGF expression by PCa epithelium and prostatic stroma * Modulation of endothelial markers (serum: E-selectin and Thrombomodulin) * Modulation of serum VEGF and urine bFGF levels, and Changes in tumor blood flow 2. epithelial compartment: * Apoptosis in prostate cancer cells (TUNEL) * Proliferation (PCNA) 3. quality of life

Eligibility

Minimum Age:

Eligible Ages: CHILD, ADULT, OLDER_ADULT

Sex: MALE

Healthy Volunteers: No

Locations

MD Anderson Cancer Center, Houston, Texas, United States

Contact Details

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: